ATE331518T1 - Methode zur behandlung von fettsucht anhand eines neurotensinreceptor-liganden - Google Patents
Methode zur behandlung von fettsucht anhand eines neurotensinreceptor-ligandenInfo
- Publication number
- ATE331518T1 ATE331518T1 AT01303855T AT01303855T ATE331518T1 AT E331518 T1 ATE331518 T1 AT E331518T1 AT 01303855 T AT01303855 T AT 01303855T AT 01303855 T AT01303855 T AT 01303855T AT E331518 T1 ATE331518 T1 AT E331518T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor ligand
- neurotensin receptor
- treating obesity
- relates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19995100P | 2000-04-27 | 2000-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE331518T1 true ATE331518T1 (de) | 2006-07-15 |
Family
ID=22739686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01303855T ATE331518T1 (de) | 2000-04-27 | 2001-04-27 | Methode zur behandlung von fettsucht anhand eines neurotensinreceptor-liganden |
Country Status (13)
Country | Link |
---|---|
US (1) | US6699832B2 (de) |
EP (1) | EP1157695B1 (de) |
JP (1) | JP2002275092A (de) |
KR (1) | KR20010098829A (de) |
AT (1) | ATE331518T1 (de) |
AU (1) | AU3888801A (de) |
CA (1) | CA2345180A1 (de) |
DE (1) | DE60121096T2 (de) |
ES (1) | ES2264679T3 (de) |
HU (1) | HUP0101666A3 (de) |
IL (1) | IL142707A0 (de) |
NZ (1) | NZ511354A (de) |
ZA (1) | ZA200103365B (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6693130B2 (en) * | 1999-02-18 | 2004-02-17 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
US8815951B2 (en) * | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
GB0107383D0 (en) * | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
NZ528147A (en) * | 2001-03-23 | 2005-06-24 | Corcept Therapeutics Inc | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
ES2320979T3 (es) * | 2001-09-24 | 2009-06-01 | Imperial Innovations Limited | Pyy-36 para la reduccion o prevencion de la obesidad. |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
EA200401345A1 (ru) * | 2002-04-10 | 2005-08-25 | Эли Лилли Энд Компани | Лечение гастропареза |
AU2003229736A1 (en) * | 2002-05-02 | 2003-11-17 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with neurotensin receptor 1 (nt1) |
AU2003240468A1 (en) * | 2002-05-02 | 2003-11-17 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with neurotensin receptor 2 (nt2) |
BR0314872A (pt) * | 2002-10-18 | 2005-08-02 | Pfizer Prod Inc | Ligandos do receptor canabinóide e usos dos mesmos |
WO2004056385A2 (en) | 2002-12-20 | 2004-07-08 | Neuronicon Aps | Modulation of activity of neurotrophins |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
CA2515368A1 (en) * | 2003-02-13 | 2004-08-26 | Luciano Rossetti | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
US20050222040A1 (en) * | 2004-04-05 | 2005-10-06 | Blm Group, Inc. | Vertebrate peptide modulators of lipid metabolism |
WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
WO2006088798A2 (en) * | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Modulation of hypothalamic atp-sensitive potassium channels |
GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
PT2120997T (pt) * | 2006-12-21 | 2017-05-05 | H Lundbeck As | Modulação da atividade de proneurotrofinas |
WO2009033808A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
US20100173829A1 (en) * | 2008-11-07 | 2010-07-08 | Aston University | Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof |
CN102307904A (zh) | 2008-12-05 | 2012-01-04 | 安吉奥开米公司 | 神经降压素或神经降压素类似物的缀合物及其用途 |
WO2011156557A2 (en) * | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
RU2013103763A (ru) | 2010-07-02 | 2014-08-10 | Ангиохем Инк. | Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения |
US8476221B2 (en) * | 2011-03-18 | 2013-07-02 | Halimed Pharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders |
CN103308670B (zh) * | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
US20150050371A1 (en) | 2012-03-09 | 2015-02-19 | Biotropics Malaysia Berhad | Extract Formulations of Rhodamnia Cinerea And Uses Thereof |
US9816090B2 (en) | 2012-11-02 | 2017-11-14 | The Brigham And Women's Hospital, Inc. | Method for inhibiting calcification of a macrophage-derived matrix vesicle |
WO2014071131A1 (en) | 2012-11-02 | 2014-05-08 | The Brigham And Women's Hospital, Inc. | Sortilin 1 is a novel inducer of vascular calcification |
JP6810146B2 (ja) * | 2015-11-24 | 2021-01-06 | トランスフェール プリュ エス.ウ.セ. | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
US10473670B2 (en) * | 2016-02-25 | 2019-11-12 | University Of Kentucky Research Foundation | Method of predicting obesity comprising measuring neurotensin |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4110321A (en) | 1976-07-12 | 1978-08-29 | Folkers Karl | Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity |
US5217953A (en) | 1990-11-30 | 1993-06-08 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Vasoactive intestinal peptide antagonist |
US5250558A (en) | 1992-01-28 | 1993-10-05 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis |
US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
US5407916A (en) | 1993-02-16 | 1995-04-18 | Warner-Lambert Company | Neurotensin mimetics as central nervous system agents |
FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
FR2760750B1 (fr) | 1997-03-17 | 1999-05-28 | Sanofi Sa | Recepteur humain a la neurotensine de type 2(hnt-r2) |
US6008050A (en) | 1997-04-02 | 1999-12-28 | Smithkline Beecham Corporation | Human neurotensin receptor type 2 and splice variants thereof |
US6274720B1 (en) * | 1997-12-31 | 2001-08-14 | Incyte Genomics, Inc. | Human preproneurotensin/neuromedin N |
US6420137B1 (en) | 1998-11-25 | 2002-07-16 | American Home Products Corporation | Nucleic acid encoding human neurotensin subtype 2 receptor |
-
2001
- 2001-04-19 IL IL14270701A patent/IL142707A0/xx unknown
- 2001-04-24 AU AU38888/01A patent/AU3888801A/en not_active Abandoned
- 2001-04-24 KR KR1020010021980A patent/KR20010098829A/ko not_active Application Discontinuation
- 2001-04-24 US US09/841,276 patent/US6699832B2/en not_active Expired - Fee Related
- 2001-04-25 CA CA002345180A patent/CA2345180A1/en not_active Abandoned
- 2001-04-25 ZA ZA200103365A patent/ZA200103365B/xx unknown
- 2001-04-26 NZ NZ511354A patent/NZ511354A/xx unknown
- 2001-04-26 HU HU0101666A patent/HUP0101666A3/hu unknown
- 2001-04-27 DE DE60121096T patent/DE60121096T2/de not_active Revoked
- 2001-04-27 JP JP2001130680A patent/JP2002275092A/ja active Pending
- 2001-04-27 EP EP01303855A patent/EP1157695B1/de not_active Revoked
- 2001-04-27 AT AT01303855T patent/ATE331518T1/de not_active IP Right Cessation
- 2001-04-27 ES ES01303855T patent/ES2264679T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU3888801A (en) | 2001-11-01 |
IL142707A0 (en) | 2002-03-10 |
US20010046956A1 (en) | 2001-11-29 |
ES2264679T3 (es) | 2007-01-16 |
DE60121096T2 (de) | 2006-12-07 |
HUP0101666A2 (hu) | 2002-02-28 |
KR20010098829A (ko) | 2001-11-08 |
JP2002275092A (ja) | 2002-09-25 |
HU0101666D0 (en) | 2001-06-28 |
EP1157695B1 (de) | 2006-06-28 |
DE60121096D1 (de) | 2006-08-10 |
US6699832B2 (en) | 2004-03-02 |
CA2345180A1 (en) | 2001-10-27 |
HUP0101666A3 (en) | 2003-03-28 |
NZ511354A (en) | 2003-03-28 |
EP1157695A1 (de) | 2001-11-28 |
ZA200103365B (en) | 2002-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE331518T1 (de) | Methode zur behandlung von fettsucht anhand eines neurotensinreceptor-liganden | |
ME02785B (me) | Humana anti-ngf neutrališuća antitela kao selektivni inhibitori ngf signalnog puta | |
ATE480255T1 (de) | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen | |
DE60223058D1 (de) | Zusammensetzungen und verfahren zur behandlung von diabetes | |
TW200738270A (en) | Method of treating depression using a TNFα antibody | |
ATE495715T1 (de) | Filtermembran mit vergrösserter oberfläche | |
EP1990059A3 (de) | Verfahren zur Behandlung von Krebs | |
EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
ATE456580T1 (de) | Verfahren zur schmerzbehandlung in knochenkrebs durch verabreichung eines ngf-antagonisten | |
ME00226B (me) | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade | |
ATE435026T1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
ATE321880T1 (de) | Nachweisverfahren für verbindungen, welche die somatostatin- und insulinproduktion stimulieren | |
DK1358177T3 (da) | Behandling af affektbetonede lidelser ved den kombinerede virkning af en nikotinreceptoragonist og et monoaminergt stof | |
WO2004009064A8 (de) | Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels | |
AU2003215190A8 (en) | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. | |
ATE462699T1 (de) | Substituierte 4,5,6,7-tetrahydro-benzothiazol-2- ylamin-verbindungen | |
DE602004024871D1 (de) | Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten | |
DE60239864D1 (de) | Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen | |
WO2006002022A3 (en) | Compositions and methods useful for the treatment of hyperglycemia | |
MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. | |
DE60036790D1 (de) | Verwendung von e5564 zur behandlung von sepsis durch intravenöse infusion | |
ATE431157T1 (de) | Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie | |
ATE294167T1 (de) | Chemische verbindungen | |
DK1377294T3 (da) | Anvendelse af neuroaktive stoffer til behandling af Parkinson's sygdom og farmaceutisk kombination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |